Completed PHASE3 INTERVENTIONAL NCT00206219

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck

Sponsor: AstraZeneca

Conditions Squamous Cell Carcinoma of the Head and Neck

Interventions Gefitinib methotrexate

Updated 6 times since 2017 Last updated: Jan 25, 2011 Started: Nov 30, 2003 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00206219, this PHASE3 trial focuses on Squamous Cell Carcinoma of the Head and Neck and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ansārinagar, India , Aurora, United States , Bangkok, Thailand , Barakaldo, Spain , Baton Rouge, United States , Bethesda, United States , Bhopal, India , Birmingham, United States , Bloemfontein, South Africa and 98 more locations